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Abstract PPARγ-agonists enhance insulin sensitivity and
improve glucose utilization in diabetic patients. Adverse
effects of PPARγ-agonists include volume retention and
edema formation. Recent observations pointed to the ability
of PPARγ agonists to enhance transcription of the serum and
glucocorticoid-inducible kinase SGK1, a kinase that is
genomically upregulated by mineralocorticoids and stimu-
lates various renal channels and transporters including the
renal epithelial Na+ channel ENaC. SGK1 has been
proposed to mediate the volume retention after treatment
with PPARγ agonists. To test this hypothesis, food contain-
ing the PPARγ agonist pioglitazone (0.02%, i.e., approxi-
mately 25 mg/kg bw/day) was administered to gene-targeted
mice lacking SGK1 (sgk1−/−, n=12) and their wild-type
littermates (sgk1+/+, n=12). According to in situ hybridiza-
tion, quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) and immunofluorescence, treatment with
pioglitazone significantly increased renal SGK1 mRNA and
protein expression in sgk1+/+ mice. The treatment increased
body weight significantly in both, sgk1+/+ mice (+2.2±0.3 g)
and sgk−/− mice (+1.3±0.2 g), and decreased hematocrit
significantly in sgk1+/+ mice (−6.5±1.0%) and sgk1−/− mice
(−3.1±0.6%). Both effects were significantly (p<0.05) more
pronounced in sgk1+/+ mice. According to Evans Blue
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distribution, pioglitazone increased plasma volume only in
sgk1+/+ mice (from 50.9±3.9 to 63.7±2.5 μl/g bw) but not
in sgk−/− mice (from 46.8±3.8 to 48.3±5.2 μl/g bw).
Pioglitazone decreased aldosterone plasma levels and blood
pressure and increased leptin plasma levels in both geno-
types. We conclude that SGK1 contributes to but does not
fully account for the volume retention during treatment with
the PPARγ agonist pioglitazone.
Keywords Serum and glucocorticoid inducible kinase .
Plasma volume . Aldosterone . Leptin . Volume retention .
PPARγ agonists
Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ)
is a ligand-dependent transcription factor that belongs to the
nuclear receptor family [4]. PPARγ is highly expressed in
white adipose tissue where it controls adipocyte differenti-
ation and lipid storage [4]. Pharmacological activation of
PPARγ by thiazolidinediones such as pioglitazone or
rosiglitazone has been shown to enhance insulin sensitivity
and to lower plasma glucose concentrations particularly in
patients with insulin resistance [11, 32, 42]. Accordingly,
PPARγ agonists are now well-established drugs widely
used in the treatment of type 2 diabetes [37, 39]. PPARγ
agonists have further been shown to decrease proteinuria
[5] and counteract renal fibrosis [30, 50].
The use of the PPARγ agonists has, however, been impeded
by their volume retaining properties [18, 22, 49]. In patients
with congestive heart failure (CHF), treatment with PPARγ
agonists was associated with decompensation and occurrence
of pulmonary edema [35]. Thus, the use of PPARγ agonists is
not recommended in patients with CHF [45].
PPARγ is expressed in kidney and is particularly
abundant in the inner medulla [20]. Therefore, the volume
retaining effect of PPARγ-agonists may be due to stimula-
tion of the epithelial sodium channel (ENaC) in the distal
nephron [26]. Accordingly, gene-targeted mice with a
collecting duct-specific deletion of PPARγ are apparently
protected against PPARγ agonists-induced fluid retention
[51].
Two mechanisms have been invoked to mediate the
stimulation of ENaC and the subsequent fluid retaining by
PPARγ activation. On the one hand, PPARγ agonists were
found to upregulate mRNA levels of SCNN1G encoding
for the gamma subunit of ENaC in a mouse inner medullary
collecting duct cell line [19]. On the other hand PPARγ
agonists have been shown to stimulate the transcription of
the serum and glucocorticoid-inducible kinase SGK1 [22],
which, in turn, was suggested to enhance the surface
expression of ENaCα [22]. In three well-established cell
culture models of the renal principal cell type, PPARγ
agonists did not alter basal or insulin-stimulated ENaC
activity and may thus be effective through additional
mechanisms [36], which, at least in theory, could be
similarly sensitive to SGK1.
SGK1 has originally been identified as a gene under
transcriptional control of glucocorticoids [15] but later
found to be genomically stimulated by mineralocorticoids
[10, 31, 34]. SGK1 is expressed in the aldosterone-sensitive
distal nephron [31], where it stimulates the epithelial Na+
channel ENaC [1, 10, 13, 29, 34]. Beyond that, SGK1 has
been shown to stimulate a wide variety of further renal and
extrarenal ion channels and transporters [28]. Gene-targeted
mice lacking SGK1 (sgk1−/−) excrete similar amounts of
salt under regular salt intake but cannot adequately decrease
renal NaCl elimination after exposure to salt-depleted diet.
As a result, salt deplete diet leads to marked decrease of
glomerular filtration rate and blood pressure in sgk1−/−
mice [46].
The present study aimed to define the in vivo role of SGK1
in the volume retaining effects of PPARγ agonists. To this
end, sgk−/− mice and their wild-type littermates (sgk1+/+)
were treated with the PPARγ agonist pioglitazone.
Materials and methods
Animal experimentation
All animal experiments were conducted according to the
guidelines of the American Physiological Society and the
German law for the welfare of animals and were approved
by local authorities.
Mice deficient in SGK1 (sgk1−/−) and their wild-type
littermates (sgk1+/+) were generated and bred as previously
described [24, 46]. They were fed a control diet (C1000,
Altromin, Lage, Germany) and had free access to tap water.
After a control period, the food pellets were replaced by
custom-made pellets containing 0.2 g/kg pioglitazone with
otherwise identical composition (C1000 + Pioglitazone,
Altromin, Lage, Germany). The drug intake approached
20–30 mg/kg bw/day, a dosage previously shown to be
effective [47].
For the evaluation of renal Na+ excretion, body weight
and fluid and food intake, sgk1−/− and sgk1+/+ mice were
placed individually in metabolic cages (Techniplast Hohen-
peissenberg, Germany) for 24-h urine collection with free
access to tap water and the respective diet [40]. Mice were
studied before treatment, during the first 8 days and after
4 weeks of pioglitazone treatment. The inner wall of the
metabolic cages was siliconized and urine was collected
under water-saturated oil. For comparison, sgk1−/− and
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sgk1+/+ mice were fed the control diet C1000 and followed
over 4 weeks.
To study the role of ENaC inhibition in pioglitazone-
induced volume retention, sgk1−/− and sgk1+/+ mice were
treated for 8 days with the ENaC blocker triamterene
(Sigma, Taufkirchen, Germany) in the drinking water
(200 mg/l, pH 4, light-protected) and the pioglitazone-
containing diet. The triamterene intake approached 35–
40 mg/kg bw/day, a dosage previously shown to be
effective [21].
To obtain blood specimens, animals were lightly
anesthetized with diethylether (Roth, Karlsruhe, Germany),
and about 150 μl of blood was withdrawn into heparinized
hematocrit capillaries by puncturing the retro-orbital plex-
us. Hematocrit was determined by centrifugation. Blood
loss was replaced with 200 μl 0.9% NaCl subcutaneously,
and the animals were allowed to recover for 2 weeks.
Expression of SGK1 was determined early (3–4 days)
after treatment to elucidate, whether alterations in SGK1
transcript levels or protein expression precede volume
expansion. Body weight was determined daily from the
beginning, and plasma hormone levels, plasma volume, and
blood pressure, 2–4 weeks after the beginning of the
treatment to disclose the effect of chronic PPARγ activation
on the respective functional parameters.
Determination of plasma volume
Plasma volume was assessed by dye dilution using Evans
Blue (Sigma, Taufkirchen, Germany). Mice were anesthe-
tized with diethylether and 30–50 μl of an Evans Blue
stock solution (3 mg/ml in 0.9% NaCl) was injected
intravenously into the left retro-orbital plexus using a
30-gauge insulin syringe (BD micro-fine, Heidelberg,
Germany). The exact applied volume was determined by
weighing the syringe before and after injection. Repeated
blood samples (20–25 μl) were drawn fom the right retro-
orbital plexus during superficial diethylether anesthesia
after 30, 60, and 100 min, which yielded a volume of
10 μl plasma after centrifugation. Absorbance was mea-
sured at 620 nm against blank mouse serum after recovery
in 90 μl phosphate-buffered saline (PBS tablets, Invitrogen,
Karslruhe, Germany). Plasma concentrations of Evans Blue
were calculated using the stock solution dissolved in mouse
serum as a standard. To correct for the clearance of Evans
Blue during distribution time, linear regression of the log
transformed concentrations was applied to calculate the
y-intercept which represents the imaginary concentration of
Evans Blue in its final distribution volume [16]. r2
approached 0.94±0.07 (SD). Division of the applied dose
of Evans Blue (in mg) by the y-intercept (in mg/ml) resulted
in the distribution volume of Evans Blue which was
normalized for body weight.
Measurement of Na+, creatinine, aldosterone, and leptin
concentrations
Plasma and urinary concentrations of Na+ were measured
by flame photometry (AFM 5051, Eppendorf, Germany)
and plasma aldosterone concentrations using a commercial
RIA kit (Demeditec, Kiel, Germany). Plasma and urinary
creatinine concentrations were measured using an enzymatic
colorimetric method (creatinine PAP, Lehmann, Berlin,
Germany). Plasma leptin levels were determined using an
ELISA kit (Linco, St. Charles, USA).
Determination of systolic blood pressure
Systolic arterial blood pressure was determined by the tail-
cuff method (IITC, Model 179, CA, USA) under control diet
and 3 weeks after treatment with pioglitazone. As reviewed
recently [33], the tail-cuff approach to determine arterial
blood pressure requires certain precautions to reduce the
stress of the animals, including appropriate training of the
mice over multiple days and adequate prewarming to dilate
the tail artery. The animals were placed in a heated chamber
at an ambient temperature of 30°C for 15 min. For each
animal, 10–20 blood pressure traces were recorded in one
session. The readings from 3 days were then averaged to
obtain a mean blood pressure under the respective
treatment. All recordings and data analysis were done using
a computerized data acquisition system and software
(PowerLab 400 and Chart 4, both AdInstruments, CO,
USA). All measurements were done by one person (FA)
during a defined time (between 2 and 4 P.M.).
Determination of plasma concentrations of pioglitazone
Quantitative determination of pioglitazone in plasma was
performed using an high performance liquid chromatogra-
phy (HPLC) tandem mass spectrometry (MS/MS) assay
after protein precipitation with methanol. A homolog was
used as internal standard (IS). Plasma samples were cleared
from any precipitates by centrifugation at 13,700×g for
5 min. After adding 15 μl of the working solution
containing IS (0.5 μg/ml in acetonitrile/water 60/40 v/v)
to 5 μl of the plasma samples, proteins were precipitated by
addition of 150 μl methanol. After centrifugation at
3,000×g for 5 min, 30 μl of the supernatant was recovered
and diluted by adding 750 μl acetonitrile/water (60/40 v/v).
An aliquot of 10 μl was injected. The HPLC system
consisted of an HTC PAL autosampler (CTC Analytics,
Zwingen, Switzerland) and an Agilent 1100 HPLC
equipment (Agilent Technologies, Böblingen, Germany).
Chromatography was performed on a Chromolith
SpeedROD® RP-18e, ID 3 mm using gradient elution.
The mobile phase consisted of two components: solvent A
Pflugers Arch - Eur J Physiol (2008) 456:425–436 427
(0.1% formic acid) and solvent B (acetonitrile). At a flow
rate of 0.8 ml/min, an isocratic period of 0.6 min at 100% A
was followed by a linear gradient (0 to 90% B/0.6 to
1.5 min) and a period from 1.5 to 3.0 min at 90% B.
Equilibration was achieved by flushing the column with
100% acetonitrile over 30 s at a flow rate of 2.0 ml/min.
Detection was performed using an Applied Biosystems
(Forster City, CA, USA) 4000 Qtrap triple quadrupole mass
spectrometer operated in the positive turbo-ion-spray mode
by applying multiple reaction monitoring (MRM). The used
mass transition for pioglitazone was 357.1 to 134.1 amu.
In situ hybridization
In situ hybridization experiments were performed to
investigate whether pioglitazone increases SGK1 transcript
levels in the kidney. Expression was studied in sgk1+/+ mice
after a 3-day treatment with pioglitazone-containing diet
corresponding to the highest slope of body weight gain.
Control mice were treated over 3 days with control diet
(n=3 each). Kidneys were harvested after retrograde
perfusion with phosphate-buffered 4% paraformaldehyde
(pH 7.4) through cannulation of the infrarenal aorta.
Anesthesia was achieved with tribromethanol (250 mg/kg
bw i.p.) and ketamin (50 mg/kg bw i.m.).
Perfused kidneys were kept in paraformaldehyde over-
night and then transferred to phosphate-buffered saline.
After embedding in paraffin-dewaxed paraffin, 5 μm tissue
sections were hybridized as described [25, 27]. The mixture
contained 35S-labeled RNA antisense murine SGK1 probe
of 1,400 bp length (500 ng/ml) in 10 mM Tris–HCl,
pH 7.4/50% (v/v) deionized formamide/600 mM NaCl/
1 mM EDTA/0.02% polyvinylpyrrolidon/0.02% Ficoll/
0.05% bovine serum albumin/10% dextrane sulfate/
10 mM dithiothreitol/denatured sonicated salmon sperm
DNA 200 μg/ml/rabbit liver tRNA 100 μg/ml. Hybridiza-
tion with RNA probes proceeded at 42°C for 18 h. Slides
were then washed and incubated for 1 h at 55°C in 2×
standard saline citrate. Nonhybridized single-stranded RNA
probes were digested by RNase A (20 μg/ml) in 10 mM
Tris–HCl, pH 8.0/0.5 M NaCl for 30 min at 37°C. Tissue
slide preparations were autoradiographed for 3 weeks and
stained with hematoxylin/eosin. Control hybridizations were
performed with the corresponding α-35S-labeled murine
SGK1 sense RNA probe. Sufficiently strong staining
required exposure periods of >14 days, which resulted in
considerable background activity, as apparent from seem-
ingly luminal staining.
Quantitative real-time PCR
To quantify SGK1 transcript levels in the kidney, treated
and untreated sgk1+/+ mice were killed after 3 days of
pioglitazone or control treatment (n=10–11 each), and the
kidneys were rapidly frozen on liquid nitrogen. PPARγ
transcript levels were quantified in untreated sgk1−/− and
sgk1+/+ mice (n=7 each). Automated disruption and
homogenization of frozen tissue of whole kidneys was
performed using the MagNa Lyser Instrument™ (Roche
Diagnostics, Mannheim, Germany). Cleared cell lysate was
transferred for further RNA purification (RNAeasy Mini
Kit, Qiagen, Hilden, Germany). Subsequently 1 μg of total
RNA was reverse transcribed to cDNA utilizing the reverse
transcription system (Bioscience, USA) with oligo(dT)
primers according to the manufacturer’s protocol. To
determine SGK1 and PPARγ transcript levels, quantitative
real-time PCR with the LightCycler System® (Roche
Diagnostics, Mannheim, Germany) was applied using the
primers 5′ TGTCTTGGGGCTGTCCTGTATG 3′ (forward)
and 5′ GCTTCTGCT GCTTCCTTCACAC 3′ (reverse) for
mSGK1, and 5′ CTGTTATGGGTGAAACTCTGGGAG 3′
(forward) and 5′ ATAGGCAGTGCATCAGCGAA 3′
(reverse) for mPPARγ [48] yielding products with 406 bp
(mSGK1) and 72 bp length (mPPARγ). PCR reactions
were performed in a final volume of 20 μl containing 2 μl
cDNA, 2.4 μl MgCl2 (3 μM), 1 μl primermix (0.5 μM of
both primers), 2 μl cDNA Master SybrGreen I mix (Roche
Molecular Biochemicals, Mannheim, Germany), and
12.6 μl DEPC-treated water. The transcript levels of the
housekeeping gene GAPDH were determined for each
sample using a commercial primer kit (Search LC, Heidel-
berg, Germany). PCR reactions for GAPDH were per-
formed in a final volume of 20 μl containing 2 μl cDNA,
2 μl primer mix (Search LC, Heidelberg, Germany), 2 μl
cDNA Master Sybr Green I mix (Roche Molecular
Biochemicals, Mannheim, Germany) and 14 μl DEPC-
treated water. The target DNA was amplified during
35 cycles of 95°C for 10 s, 68°C for 10 s, and 72°C for
16 s, each with a temperature transition rate of 20°C/s, a
secondary target temperature of 58°C, and a step size of
0.5°C. Melting curve analysis was performed at 95°C, 0 s;
58°C, 10 s; 95°C, 0 s to determine melting temperatures of
primer dimers and the specific PCR products. Melting
curve analysis confirmed the amplified products. Finally,
results were calculated as a ratio of the target vs house
keeping gene GAPDH transcripts.
Immunofluorescence
For the analysis of SGK1 protein expression in the kidney,
sgk1+/+ and sgk1−/− mice were killed after 3 days of
pioglitazone or control treatment (n=3 each) and the
kidneys were rapidly frozen on liquid nitrogen. For
comparison, mice treated with a low-salt diet (C1036,
Altromin, Lage, Germany) for 4 days were killed (n=2
each). Frozen sections (3 μm) were fixed in acetone
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(10 min; −20°C), air-dried and incubated in Tris buffer for
5 min. Then, blocking was performed with normal goat
serum (blotto, 1:5, 45 min). Afterwards, the primary
antibody (rabbit anti-SGK1, 1:50) was applied (1 h; 37°C)
and the sections were washed in Tris buffer (3×5 min).
Polyclonal monospecific antibodies against the SGK1
protein were raised by a commercial antibody service (Dr.
Pineda, Berlin, Germany) as previously described [25].
Briefly, rabbits were immunized with an oligopeptide
(N-terminally cysteine-linked to hemocyanin) encoding
the amino acids 128–146 of mouse and human SGK1
(GeneBank accession nos. AF205855 and AX002570),
respectively. Purified IgG fractions were tested for mono-
specificity by immunoblot of lysates from HEK 293 cells
transfected with hSGK1. Afterwards, the secondary anti-
body (goat anti-rabbit, Alexa 488, 1:200) was applied for
30 min. 11β steroid dehydrogenase was probed with a
commercially available sheep anti-11β HSD antibody (AB
1296, Chemicon) and a secondary biotinylated anti-sheep
antibody with subsequent detection by Streptavidin-Alexa
568. DAPI was used to stain nuclei (1:1,000 in distilled
water for 5 min) followed by rinsing in Tris buffer (3×
5 min). Finally, sections were covered with mowiol and
analyzed.
Statistical analysis
Data are provided as means±SEM; n represents the number
of independent experiments. All data were tested for
normality using the Kolmogorov–Smirnow test and, for
significance, using two-tailed paired or unpaired Student
t test and Welch’s correction or ANOVA, where required,
using GraphPad InStat version 3.00 for Windows 95,
GraphPad Software, San Diego California USA, http://
www.graphpad.com. A p value less than 0.05 was
considered statistically significant. Linear regression was
also calculated utilizing GraphPad InStat version 3.00.
Results
Quantitative reverse transcriptase-polymerase chain reaction
(RT-PCR) revealed similar PPARγ transcript levels in kidneys
from sgk1+/+ and sgk1−/− mice. Absolute PPARγ mRNA
Fig. 1 Effect of pioglitazone on renal SGK1 transcript levels. a In situ
hybridization showing kidney tissue of cortex (150-fold magnifica-
tion) and medulla (250-fold magnification) probed with radiolabeled
mSGK1 antisense. b, c Arithmetic means±SEM (n=10–11 each
group) of absolute GAPDH and SGK1 copies and the ratio of SGK1
transcript levels over GAPDH transcript levels in treated (closed
column) and untreated (open column) sgk1+/+ animals. Number sign
indicates significant difference between control and pioglitazone
treatment
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levels in whole kidneys were 15±3 copies in sgk1−/− (n=7)
and 16±8 copies in sgk1+/+ mice (n=7). Normalized for
GAPDH transcript levels, the expression was 0.11±0.07
copies/103 GAPDH in sgk1−/− and 0.11±0.05 copies/103
GAPDH in sgk1+/+ mice. Similarly, plasma concentrations
of pioglitazone, as determined by HPLC, were not signifi-
cantly different between the genotypes. After a 10-day
treatment, plasma concentrations were 15.4±0.4 μM in
sgk1+/+ mice and 12.2±2.5 μM in sgk1−/− mice (n=3 each).
Similar values were obtained after a 4-week treatment
(11.3±1.5 μM in sgk1+/+ mice and 10.1±0.9 μM in
sgk1−/− mice, n=6 each).
To determine, whether pioglitazone influences the
transcript levels of SGK1, renal tissue was analyzed in
sgk1+/+ mice by in situ hybridization and quantitative RT-
PCR after a 3-day treatment with pioglitazone. As shown in
Fig. 1a, pioglitazone treatment increased SGK1 mRNA
abundance in the collecting duct of the renal medulla. In the
sections of renal cortex, SGK1 expression tended to be
stronger in the distal tubules and connecting ducts of treated
mice, whereas no difference was visible between treated
and untreated animals in glomeruli and proximal tubules.
According to quantitative RT-PCR, pioglitazone treatment
significantly increased SGK1 transcript levels in whole
kidneys (1,989±528 copies in untreated, 4,474±1047
copies in treated mice) without significantly affecting
GAPDH mRNA levels (218,828±51,606 copies in untreat-
ed, 280,563±55,101 copies in treated mice, Fig. 1b).
Expressed as a ratio of SGK1 over GAPDH, SGK1
transcript levels were induced by a factor of 1.7 (Fig. 1c).
The increase in SGK1 transcript levels was paralleled by an
increased SGK1 protein expression as evidenced by
enhanced immunofluorescence in kidney sections from
pioglitazone-treated sgk1+/+ mice (Fig. 2). Staining was
Fig. 2 Effect of pioglitazone on renal SGK1 protein expression. a
Immunofluorescence of kidney sections with antibodies directed
against 11β-hydroxysteroid dehydrogenase type 2 (red fluorescence)
and SGK1 (green fluorescence) in the distal nephron. Nuclei are
stained blue with DAPI. b Immunofluorescence of kidney sections
with anti-SGK1 antibody (green fluorescence) from sgk1+/+ and
sgk1−/− mice treated with control diet, pioglitazone-containing diet for
3 days or low salt diet for 4 days (tenfold magnification). Nuclei are
stained blue with DAPI
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confined to the distal nephron as confirmed by colocaliza-
tion with 11β-hydroxysteroid dehydrogenase type 2. The
intensity of the staining after pioglitazone treatment was
similar to that obtained in kidneys from mice treated with a
low-salt-diet, a maneuver-stimulating aldosterone secretion
and SGK1 protein expression. In kidneys from sgk1−/−
mice, no specific staining was obtained.
If pioglitazone treatment was followed by extracellular
volume expansion, then the treatment should increase body
weight. As illustrated in Fig. 3, body weight indeed increased
during the treatment in both, sgk1+/+ and sgk1−/−mice.
However, the increase of body weight was significantly
more pronounced in sgk1+/+ mice than in sgk1−/−mice both
after 8-day (+1.5±0.2 g, vs +1.0±0.2 g, n=12 each) and
4-week (+2.2±0.3 g, vs +1.3±0.2 g, n=12 each; Fig. 3a)
treatment. During control experiments, no appreciable net
body weight gain was observed after 8 days or 4 weeks
(Fig. 3a and b). After simultaneous treatment with the ENaC
blocker triamterene and pioglitazone, body weight was
decreased in both genotypes to a similar extent during the
first 3 days (Fig. 3a). After that, sgk1−/− mice continued to
lose weight, whereas sgk1+/+ mice restored their body
weight and returned to their baseline weight.
Extracellular volume expansion should further increase
plasma volume and, thus, decrease hematocrit. Pioglitazone
treatment indeed decreased the hematocrit significantly in
both, sgk1+/+ and sgk1−/− mice (Table 1). The effect was,
however, again significantly more pronounced in sgk1+/+
mice (−6.5±1.0%, n=12) than in sgk1−/− mice (−3.1±
0.6%, n=12) after 4 weeks of treatment. Plasma
Na+ concentration increased significantly in sgk1+/+ mice
and tended to increase in sgk1−/− mice (Table 1).
To assess plasma volume directly, a dye dilution method
using Evans Blue was applied. The dye tightly binds to plasma
proteins (mainly albumin) and is thus a reliable indicator for
plasma volume. As illustrated in Fig. 4, pioglitazone treatment
increased significantly the ratio of plasma volume/body
weight in sgk1+/+ mice, but not in sgk1−/−mice.
Extracellular volume expansion should decrease aldo-
sterone release. As reported earlier [46], plasma aldosterone
concentration was higher in sgk1−/− than in sgk1+/+ mice
before pioglitazone administration (Fig. 5). Pioglitazone
treatment significantly decreased plasma aldosterone values
in both genotypes. However, plasma aldosterone levels
remained significantly higher in sgk1−/− mice after treat-
ment. The decrease of plasma aldosterone concentration
tended to be larger in sgk1+/+ mice than in sgk1−/− mice, a
difference, however, not reaching statistical significance.
Even though pioglitazone treatment induced extracellular
volume expansion, it significantly decreased blood pressure
from 112±4 to 95±4 mmHg in sgk1+/+ mice (by −14.3±
3.7 mmHg, n=12) and from 102±4 to 90±2 mmHg in
sgk1−/− mice (by −19.2±4.8 mmHg, n=12). The decrease
of blood pressure tended to be larger in sgk1−/− than in
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sgk1+/+ control
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Fig. 3 Alterations of body weight after pioglitazone treatment. a
Arithmetic means±SEM (n=9–12) of body weight of sgk1−/− mice
(closed symbols) and sgk1+/+ mice (open symbols) within the first
8 days of control, pioglitazone (PIO) or pioglitazone + triamterene
(PIO + triam) treatment. Number sign indicates significant difference
between control and pioglitazone treatment. Asterisk indicates signif-
icant difference between sgk1−/− vs sgk1+/+ mice. For clarity, symbols
for significance were only depicted in the body weight at the last day
of treatment (day 8). b Arithmetic means±SEM (n=9–12) of the
alterations of body weight after 28 days of pioglitazone or control
treatment in sgk1−/− mice (closed bars) and sgk1+/+ mice (open bars)
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sgk1+/+ mice, a difference, however, not reaching statistical
significance (Fig. 6).
As leptin is released from adipocytes, plasma leptin
concentrations increase with adipocyte mass. Pioglitazone
treatment increased plasma leptin concentrations in both
genotypes to a similar extent (Fig. 7).
Discussion
The present observations disclose an influence of the serum
and glucocorticoid inducible kinase SGK1 on the volume-
retaining effect of pioglitazone. Pioglitazone treatment
increased renal SGK1 mRNA and protein expression,
which is apparently required for the full effect of the
PPARγ agonist on extracellular fluid volume.
Differences in the observed effects between sgk1+/+ and
sgk1−/− mice were not attributable to differences in PPARγ
expression or pioglitazone plasma levels. The latter were in
the lower micromolar range (10–15 μM), which is
comparable to levels measured in volunteers after oral
ingestion of 30 mg pioglitazone (3 μM; [44]). At those
concentrations, pioglitazone does increase extracellular
fluid volume, as previously shown for PPARγ agonists
[18, 22, 49].
According to the present study, SGK1 may contribute to,
but does not fully account for, the fluid retaining effects of
pioglitazone. Volume retention was estimated from body
Table 1 Biometric parameters before and after pioglitazone treatment
Parameter sgk1+/+ sgk1−/−
Control Treatment Control Treatment
Body Weight (g) 26.2±1.2 28.3±1.1a 24.7±1.3 25.9±1.3a
Food intake (g/24 h) 3.37±0.2 3.91±0.3a 3.69±0.2 3.93±0.2
Fluid Intake (ml/24 h) 3.95±0.5 4.88±0.7a 3.85±0.3 4.13±0.3
Urinary output (ml/24 h) 1.75±0.3 1.85±0.3 1.75±0.2 1.80±0.2
Hematocrit (%) 54.6±0.9 48.1±0.9a 52.1±0.4 49.1±0.6a
[Na+]plasma (mM) 149±2 157±3a 154±2 158±2
24h-creatinine clearance (μl/min) 114±13 110±10 148±25 95±13
Urinary Na+ excretion
(μmol/24 h)
234±17 316±22a 270±24 282±22
Fractional excretion Na+(%) 0.94±0.12 1.72±0.16a 1.01±0.15 1.44±0.16a
Arithmetic means±SEM (n=12 each) of body weight, food and fluid intake, hematocrit, plasma Na+ concentrations, renal excretion of Na+ and
creatinine clearance in SGK1 knockout mice (sgk1−/− ) and their wild-type littermates (sgk1+/+ ) before and after 4 weeks of pioglitazone treatment,
a Indicates significant difference between control and treatment with pioglitazone
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Fig. 4 Plasma volume determined using Evans Blue. a Representa-
tive experiment demonstrating the time-dependent decay of Evans
Blue plasma concentration. b Arithmetic means±SEM (n=9 each
group) of relative plasma volume (per gram body weight) of sgk1−/−
mice (closed columns) and sgk1+/+ mice (open columns) before and
3 weeks after pioglitazone treatment. Asterisk indicates significant
difference between sgk1−/− vs sgk1+/+ mice. Number sign indicates
significant difference between control and treatment with pioglitazone
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weight, hematocrit, plasma aldosterone concentrations, and
by direct determination of the plasma volume. Whereas the
first three parameters pointed to some volume retention in
sgk1−/− mice, plasma volume increased significantly only
in sgk1+/+ mice. The differences may reflect methodolog-
ical limitations in the analysis of volume retention. The
effects of pioglitazone on body weight, hematocrit, and
plasma aldosterone concentration in sgk1−/− mice point to
SGK1-independent effects of pioglitazone on sodium and
fluid reabsorption. ENaC activity and expression was found
to be directly stimulated by pioglitazone in a mouse
collecting duct cell line [19], but not in other studies using
CCD principal cell lines [36]. Treatment with triamterene
prevented the body weight gain in sgk1+/+ mice, an
observation indeed pointing to the involvement of ENaC
in pioglitazone-induced volume retention. ENaC is regulat-
ed by SGK1, which stimulates ENaC expression and
activity [1, 10, 13, 29, 34]. Interestingly, sgk1−/− mice
under combined treatment were more susceptible to the
diuretic action of triamterene and continued to lose weight
over the treatment period. The sensitivity of sgk1−/− mice to
triamterene mice clearly points to SGK1 independent ENaC
activity. Beyond that, the possibility must be considered that
the volume retaining activity of SGK1 is not exclusively due
to stimulation of ENaC. As a matter of fact, in vitro
experiments disclosed the ability of SGK1 to stimulate a
wide variety of carriers and channels [28] including the renal
tubular Na+, K+, 2Cl− cotransporter [29].
The actions of the PPARγ agonist pioglitazone on the
distal nephron strongly resemble the actions of aldosterone,
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means ± SEM (n=12 each
group) of plasma aldosterone
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mice (open columns) before and
2 weeks after pioglitazone treat-
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Fig. 6 Systolic blood pressure. a Arithmetic means±SEM (n=12
each group) of systolic blood pressure in sgk1−/− (closed columns) and
sgk1+/+ mice (open columns) before (control) and 3 weeks after
pioglitazone treatment. Number sign indicates significant difference
between control and treatment with pioglitazone, Asterisk indicates
significant difference between sgk1−/− vs sgk1+/+ mice. b Arithmetic
means±SEM (n=12 each group) of the change of systolic blood
pressure in sgk1−/− (closed columns) and sgk1+/+ mice (open columns)
after 3 weeks pioglitazone treatment
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which also exerts both, SGK1-independent direct [3] and
SGK1-dependent indirect effects on ENaC expression and
activity [1, 10, 13, 29, 34]. As part of a counter-regulation
to the pioglitazone-induced volume retention, endogenous
aldosterone levels were suppressed. However, plasma
aldosterone levels remained significantly higher in sgk1−/−
mice under pioglitazone treatment.
The administration of pioglitazone sensitizes tissues for
the action of insulin [11, 32, 42]. The effects of aldosterone
and insulin or IGF-1 may be additive [17]. Insulin
stimulates SGK1 and is thus expected to enhance ENaC
activity and renal Na+ reabsorption [6–8]. SGK1 contrib-
utes to the regulation of renal Na+ excretion by aldosterone,
insulin, and IGF-1. As the effect of aldosterone is only
partially dependent on the presence of SGK1, the effects of
aldosterone and SGK1 may be additive. However, ADH or
insulin do not further stimulate ENaC in cells expressing
constitutively active SGK1 [2].
Along those lines, acute intravenous application of
insulin (under euglycemic conditions) significantly de-
creased fractional urinary Na+ excretion without affecting
blood pressure and GFR in sgk1+/+ mice, an effect
significantly blunted in sgk1−/− mice [23]. Those experi-
ments demonstrate a critical role of SGK1 in insulin-
induced renal Na+ retention. In contrast, PPARγ agonists
showed no effect on basal or insulin-stimulated ENaC
activity [36].
The salt retaining effects of PPARγ agonists were
expected to increase blood pressure. The opposite is
observed, i.e., decrease of blood pressure. A hypotensive
effect of PPARγ agonists is similarly observed in clinical
studies and may be due to a vasodilating effect of PPARγ
agonists [38]. Even though the blood pressure lowering
effect is apparent in both, sgk1−/− and sgk1+/+ mice, it is
more pronounced in sgk1−/− mice. Thus, SGK1 counteracts
the blood pressure-lowering effect of pioglitazone.
The salt-retaining effect of SGK1 is expected to impact
on blood pressure control. As a matter of fact, SGK1
expression is deranged in the salt sensitive Dahl rat [14].
Moreover, moderately enhanced blood pressure values are
observed in individuals carrying a variant of the SGK1
gene, affecting some 3–5% of unselected Caucasians [9,
43]. Interestingly, the gene variant is associated with
enhanced insulin sensitivity of blood pressure [43].
SGK1 does not only participate in electrolyte balance by
its influence on renal elimination, but mediates at least, in
part, the effect of mineralocorticoids on salt appetite [41].
Thus, SGK1 plays a dual role in mineralocorticoid-
regulated NaCl homeostasis. Whether enhanced salt appe-
tite contributes to extracellular volume expansion under
PPARγ treatment, cannot be decided on the basis of our
observations. Pioglitazone leads to enhanced food and,
thus, salt intake, an effect presumably accounting for the
enhanced urinary Na+ elimination during pioglitazone
treatment.
Leptin levels were elevated during pioglitazone treat-
ment, to a similar extent, in both genotypes. The increase of
leptin levels may point to an increase in white adipocyte
mass, as leptin levels positively correlate with white fat
mass [12]. This also implies that the observed body weight
gain does not fully represent volume retention but also
reflects an increase in white adipocyte mass. The SGK1-
independent effect of PPARγ agonists on white fat mass
may have contributed to the gain of body weight.
In conclusion, PPARγ agonists upregulate expression of
SGK1, which contributes to but does not fully account for
extracellular volume expansion after treatment with these
drugs.
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